author

Geordie Carragher

Geordie Carragher is a staff writer for Cantech Letter

The Latest From Geordie Carragher

Analysts Pharma and Biotech hls

HLS Therapeutics gets target drop, still a Buy, says Clarus

Analysts Health vhi

VitalHub is a Buy, says Beacon Securities

Analysts Health crbk

Carebook Technologies gets target cut by iA Capital

Analysts Cannabis db

Decibel Cannabis is a Buy, says Raymond James

Analysts Cannabis DNA

Ginkgo Bioworks has a huge runway ahead, says Raymond James

Analysts Marketing at

AcuityAds is over a double from here, says Echelon

Analysts ifx

Imaflex is heading higher, says Beacon

Analysts quis

Quisitive Technology Solutions has a 125 upside, says Beacon

Analysts Cannabis vext

US cannabis name Vext Science keeps Buy rating from Haywood

Analysts Health pink

Perimeter Medical gets a target cut from Paradigm

Analysts Cannabis ndva

Cannabis company Indiva is a Buy, says Raymond James

Analysts MGRO

Still more upside to MustGrow Biologics, says Research Capital

Analysts Crypto bigg

BIGG Digital Assets is a Buy in crypto, says PI Financial

Analysts Cannabis vlns

The Valens Company is good for a triple, says Haywood

Analysts Health hls

HLS Therapeutics is a Buy, says Stifel

Analysts Health ops

OpSens selloff has been overdone, says Paradigm

Analysts Cleantech heo

H2O Innovation is a Buy, according to Beacon Securities

Analysts Health care

Dialogue Health Technologies scores a target raise from Laurentian Bank

Analysts Cannabis vlns

The Valens Company has a huge upside, according to ATB Capital

Analysts Health NEWU

Newtopia stock downgraded by Research Capital

Analysts Crypto voyg

Voyager Digital has target trimmed by Eight Capital

Analysts Cleantech uge

UGE International has a 171 per cent upside, says iA Capital

Analysts Pharma and Biotech tlt

Theralase Technologies receives a target raise from Research Capital

Analysts Health gtms

Greenbrook TMS has a 92 per cent upside, says Clarus

Analysts Marketing wish

We’re bullish on Wishpond Technologies, says Beacon

Analysts Software cts

Converge Technology Solutions wins a target raise from Laurentian Bank

Analysts Health drdr

MCI Onehealth keeps Speculative Buy rating with Echelon Capital

Analysts Software vqs

VIQ Solutions has tons of upside, says Paradigm Capital

Analysts Cannabis trul

Trulieve Cannabis is more than a double, says Echelon

Analysts Cannabis ffnt

4Front Ventures has target clipped by Haywood Capital

AIDX

Share

Tweet

Share

Get Stock Picks from the Pros. In your Inbox.